Successfully planning and executing a conference or event requires a business team to consider both the macro and micro details.

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to the ...